Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis

Revista Brasileira de Reumatologia

Volumn 52, Issue 4, 2012, Pages 580-593

  Pereira, Rosa Maria Rodrigues ^a   de Carvalho, Jozélio Freire ^a   Paula, Ana Patrícia ^b   Zerbini, Cristiano ^a   Domiciano, Diogo S ^c   Gonçalves, Helenice ^d   Danowski, Jaime S ^e   Marques Neto, João F ^f,g   Mendonça, Laura M C ^h   Bezerra, Mailze C ^a,i,j   Terreri, Maria Teresa ^a,k   Imamura, Marta ^a   Weingrill, Pedro ^l   Plapler, Perola G ^a   Radominski, Sebastião ^m   Tourinho, Tatiana ⁿ   Szejnfeld, Vera L ^o   Andrada, Nathalia C ^p  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

^c FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^d Medical Association of Brasília AMBr   (Brazil)

^e Hospital Israelita Albert Sabin   (Brazil)

^f UNIVERSITY OF CAMPINAS   (Brazil)

^g PONTIFÍCIA UNIVERSIDADE CATÓLICA DE CAMPINAS   (Brazil)

^h FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

ⁱ HOSPITAL GERAL DE FORTALEZA   (Brazil)

^j UNIVERSITY OF FORTALEZA   (Brazil)

^k UNIVERSITY OF FREIBURG   (Germany)

^l Medical School   (Brazil)

^m FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

ⁿ UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^o FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^p Brazilian Medical Association   (Brazil)

more..

Author keywords

Glucocorticoid; Osteoporosis; Treatment

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; COLECALCIFEROL; ERGOCALCIFEROL; GLUCOCORTICOID; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISONE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

ALCOHOL CONSUMPTION; ARTICLE; BONE DENSITY; BONE MASS; CHILD HEALTH CARE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; COMPLEX REGIONAL PAIN SYNDROME; CORTICOSTEROID INDUCED OSTEOPOROSIS; DENSITOMETRY; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; FEVER; FLU LIKE SYNDROME; FRACTURE RISK ASSESSMENT TOOL; HIP FRACTURE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LACTATION; LIFESTYLE MODIFICATION; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; OSTEOPENIA; PATIENT COMPLIANCE; POSTMENOPAUSE; PRACTICE GUIDELINE; PREGNANCY; PREMENOPAUSE; PRIMARY PREVENTION; RESISTANCE TRAINING; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SEDENTARY LIFESTYLE; SEX DIFFERENCE; SINGLE DRUG DOSE; SMOKING; SPINE FRACTURE; SPINE RADIOGRAPHY; SYSTEMATIC REVIEW; T SCORE; TERATOGENICITY; UNSPECIFIED SIDE EFFECT; VERTEBRAL FRACTURE ASSESSMENT;

GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS;

EID: 84866492201     PISSN: 04825004     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0482-50042012000400009     Document Type: Article

References (82)

1. Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996; 313(7053):344-6.
2. van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13(10):777-87.
3. Kaji H, Yamauchi M, Chihara K, Sugimoto T. The threshold of bone mineral density for vertebral fracture in female patients with glucocorticoid-induced osteoporosis. Endocr J 2006; 53(1):27-34.
4. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003; 48(11):3224-9.
5. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fracture. June, 2000. J Bone Miner Res 2005; 20(8):1487-94.
6. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001; 44(7):1496-503.
7. Adler RA, Hochberg MC. Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs. Arch Intern Med 2003; 163(21):2619-24.
8. Geusens PP, de Nijs RN, Lems WF, Laan RF, Struijs A, van Staa TP et al. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis 2004; 63(3):324-5.
9. National Osteoporosis Society & Royal College of Physicians guidelines working group for Bone and Tooth Society. Glucocorticoidinduced Osteoporosis: guidelines for prevention and treatment. London, Royal College of Physicians, 2002.
10. Devogelaer JP, Goemaere S, Boonen S, Body JJ, Kaufman JM, Reginster JY et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 2006; 17(1):8-19.
11. Nawata H, Soen S, Takayanagi R, Tanaka I, Takaoka K, Fukunaga M et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J Bone Miner Metab 2005; 23(2):105-9.
12. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62(11):1515-26.
13. Sambrook P, Birmingham J, Kelly P, Kempler S, Pocock N, Eisman J. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol and calcitonin. N Engl J Med 1993; 328(24): 1747-52.
14. Yeap SS, Fauzi AR, Kong NC, Halim AG, Soehardy Z, Rahimah I et al. A comparison of calcium, calcitriol, and alendronate in corticosteroid-treated premenopausal patients with systemic lupus erythematosus. J Rheumatol 2008; 35(12):2344-7.
15. Poulos P, Adachi JD. Guidelines for the prevention and therapy of glucocorticoid-induced osteoporosis. Clin Exp Rheumatol 2000; 18(Suppl. 21): S79-S86.
16. Richy F, Ethgen O, Bruyere O, Reginster JY. Effi cacy of alfacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 2004; 15(4):301-10.
17. Sambrook P, Henderson NK, Keogh A, MacDonald P, Glanville A, Spratt P et al. Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res 2000; 15(9):1818-24.
18. de Nijs RN, Jacobs JW, Algra A, Lems WF, Bijlsma JW. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 2004; 15(8):589-602.
19. Ringe JD, Dorst A, Faber H, Schacht E, Rahlfs VW. Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoidinduced osteoporosis. Rheumatol Int 2004; 24(2):63-70.
20. Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000; (2):CD000952.
21. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low dose corticosteroids in patients with rheumatoid arthritis. Ann Intern Med 1996; 125(12):961-8.
22. Jensen J, Christiansen C, Rødbro P. Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause. N Engl J Med 1985; 313(16):973-5.
23. Korkor AB, Eastwood D, Bretzmann C. Effects of gender, alcohol, smoking, and dairy consumption on bone mass in Wisconsin adolescents. WMJ 2009; 108(4):181-8.
24. Teucher B, Dainty JR, Spinks CA, Majsak-Newman G, Berry DJ, Hoogewerff JA et al. Sodium and bone health: impact of moderately high and low salt intakes on calcium metabolism in postmenopausal women. J Bone Miner Res 2008; 23(9):1477-85.
25. Pongchaiyakul C, Nguyen TV, Kosulwat V, Rojroongwasinkul N, Charoenkiatkul S, Eisman JA et al. Effects of physical activity and dietary calcium intake on bone mineral density and osteoporosis risk in a rural Thai population. Osteoporos Int 2004; 15(10):807-13.
26. Ensrud KE, Ewing SK, Taylor BC, Fink HA, Stone KL, Cauley JA et al. Frailty and risk of falls, fracture, and mortality in older women: the study of osteoporotic fractures. J Gerontol A Biol Sci Med Sci 2007; 62(7):744-51.
27. Morin S, Tsang JF, Leslie WD. Weight and body mass index predict bone mineral density and fractures in women aged 40 to 59 years. Osteoporos Int 2009; 20(3):363-70.
28. Hodgson SF, Watts NB, Bilezikian JP, Clarke BL, Gray TK, Harris DW et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003; 9(6):544-64.
29. Kohrt WM, Bloomfield SA, Little KD, Nelson ME, Yingling VR; American College of Sports Medicine. American College of Sports Medicine Position Stand: physical activity and bone health. Med Sci Sports Exerc 2004; 36(11):1985-96.
30. Schmitt NM, Schmitt J, Dören M. The role of physical activity in the prevention of osteoporosis in postmenopausal women. An update. Maturitas 2009; 63(1):34-8.
31. Gillespie LD, Robertson MC, Gillespie WJ, Lamb SE, Gates S, Cumming RG et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2009; 15(2):CD007146.
32. Maricic M. Glucocorticoid-induced osteoporosis: treatment options and guidelines. Curr Osteoporos Rep 2005; 3(1):25-9.
33. Braith RW, Magyari PM, Fulton MN, Aranda J, Walker T, Hill JA. Resistance exercise training and alendronate reverse glucocorticoidinduced osteoporosis in heart transplant recipients. J Heart Lung Transplant 2003; 22(10):1082-90.
34. Newman ED, Matzko CK, Olenginski TP, Perruquet JL, Harrington TM, Maloney-Saxon G et al. Glucocorticoid-Induced Osteoporosis Program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 year. Osteoporos Int 2006; 17(9):1428-34.
35. de Jong Z, Munneke M, Lems WF, Zwinderman AH, Kroon HM, Pauwels EK et al. Slowing of bone loss in patients with rheumatoid arthritis by long-term high-intensity exercise: results of a randomized, controlled trial. Arthritis Rheum 2004; 50(4):1066-76.
36. Angeli A, Guglielmi G, Dovio A, Capelli G, de Feo D, Giannini S et al. High prevalence of asymptomatic vertebral fractures in postmenopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 2006; 39(2):253-9.
37. Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi ML et al. International Society for Clinical Densitometry 2007 Adult and Pediatric Offi cial Positions. Bone 2008; 43(6):1115-21.
38. Reid DM, Adami S, Devogelaer JP, Chines AA. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int 2001; 69(4):242-7.
39. Cruse LM, Valeriano J, Vasey FB, Carter JD. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men. J Clin Rheumatol 2006; 12(5):221-5.
40. Van Staa, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of Oral Corticosteroids and Risk of Fracture. J Bone Min Res 15; 6:2000.
41. van Staa TP, Cooper C, Leufkens HG, Bishop N. Children and the risk of fractures caused by oral corticosteroids. J Bone Miner Res 2003; 18(5):913-8.
42. Blodgett FM, Burgin L, Iezzoni D, Gribetz D, Talbot NB. Effects of prolonged cortisone therapy on the statural growth, skeletal maturation and metabolic status of children. N Engl J Med 1956; 254(14):636-41.
43. Varonos S, Ansell BM, Reeve J. Vertebral collapse in juvenile chronic arthritis: its relationship with glucocorticoid therapy. Calcif Tissue Int 1987; 41(2):75-8.
44. Baim S, Binkley N, Bilezikian JP, Kendler DL, Hans DB, Lewiecki EM et al. Offi cial Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference. J Clin Densitom 2008; 11(1):75-91.
45. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S et al. Alendronate for the prevention and treatment of glucocorticoidinduced osteoporosis. N Engl J Med 1998; 339(5):292-9.
46. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999; 42(11):2309-18.
47. de Nijs RN, Jacobs JW, Lems WF, Laan RF, Algra A, Huisman AM et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006; 355(7):675-84.
48. Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000; 67(4):277-85.
49. Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 2001; 44(1):202-11.
50. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999; 42(11):2309-18.
51. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356(18):1809-22.
52. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 2007; 357:1799-809.
53. Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009; 373(9671):1253-63.
54. Rietbrock S, Olson M, van Staa TP. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. QJM 2009; 102(1):35-42.
55. Lau AN, Adachi JD. Role of teriparatide in treatment of glucocorticoid-induced osteoporis. Ther Clin Risk Manag 2010; 6:497-503.
56. Canalis E, Giustina A, Bilezikian IP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007; 357(9):905-16.
57. Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357(20):2028-39.
58. Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009; 60(11):3346-55.
59. Langdahl BL, Marin F, Shane E, Dobnig H, Zanchetta JR, Maricic M et al. Teriparatide versus alendronate for treating glucorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporosis Int 2009; 20(12):2095-104.
60. Maricic M, Gluck O. Densitometry in glucocorticoid-induced osteoporosis. J Clin Densitometry 2004; 7(4):359-63.
61. Franchimont N, Canalis E. Management of glucocorticoid induced osteoporosis in premenopausal women with autoimmune disease. Autoimmun Rev 2003; 2(4):224-8.
62. Winzenberg T, Oldenburg B, Frendin S, De Wit L, Riley M, Jones G. The effect on behavior and bone mineral density of individualized bone mineral density feedback and educational interventions in premenopausal women: a randomized controlled trial [NCT00273260]. BMC Public Health 2006; 6-12.
63. Okada Y, Nawata M, Nakayamada S, Saito K, Tanaka Y. Alendronate protects premenopausal women from bone loss and fracture associated with high-dose glucocorticoid therapy. J Rheumatol 2008; 35(11):2249-54.
64. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R et al. Intermittent etidronate therapy to prevent corticosteroidinduced osteoporosis. N Engl J Med 1997; 337(6):382-7.
65. Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 1999; 60(2):68-73.
66. Minsker DH, Manson JM, Peter CP. Effects of the bisphosphonate, alendronate, on parturition in the rat. Toxicol Appl Pharmacol 1993; 121(2):217-23.
67. Chan B, Zacharin M. Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: a report of four cases. J Clin Endocrinol Metab 2006; 91(6):2017-20.
68. Ornoy A, Wajnberg R, Diav-Citrin O. The outcome of pregnancy following pre-pregnancy or early pregnancy alendronate treatment. Reprod Toxicol 2006; 22(4):578-9.
69. Dunlop DJ, Soukop M, McEwan HP. Antenatal administration of aminopropylidene diphosphonate. Ann Rheum Dis 1990; 49(11): 955.
70. Illidge TM, Hussey M, Godden CW. Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate. Clin Oncol (R Coll Radiol) 1996; 8(4):257-8.
71. Munns CF, Rauch F, Ward L, Glorieux FH. Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 2004; 19(10):1742-5.
72. Djokanovic N, Klieger-Grossmann C, Koren G. Does treatment with bisphosphonates endanger the human pregnancy? J Obstet Gynaecol Can 2008; 30(12): 1146-8.
73. Levy S, Fayez I, Taguchi N, Han JY, Aiello J, Matsui D et al. Pregnancy outcome following in utero exposure to bisphosphonates. Bone 2009; 44(3):428-30.
74. Yarrington JT, Capen CC, Black HE, Re R, Potts JT Jr, Geho WB. Experimental parturient hypocalcemia in cows following prepartal chemical inhibition of bone resportion. Am J Pathol 1976; 83(3):569-88.
75. Bianchi ML. How to manage osteoporosis in children. Best Pract Res Clin Rheumatol 2005; 19(6):991-1005.
76. Brown JJ, Zacharin MR. Attempted randomized controlled trial of pamidronate versus calcium and calcitriol supplements for management of steroid-induced osteoporosis in children and adolescents. J Paediatr Child Health 2005; 41(11):580-2.
77. Roth J, Bechtold S, Borte G, Dressler F, Girschick H, Borte M. Diagnosis, prophylaxis and therapy of osteoporosis in juvenile idiopathic arthritis: consensus statement of the German Association for Pediatric Rheumatology. Z Rheumatol 2007; 66(5):434-40.
78. Bianchi ML, Cimaz R, Bardare M, Zulian F, Lepore L, Boncompagni A et al. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum 2000; 43(9):1960-6.
79. Rudge S, Hailwood S, Horne A, Lucas J, Wu F, Cundy T. Effects of once-weekly oral alendronate on bone in children on glucocorticoids treatment. Rheumatology (Oxford) 2005; 44(6):813-8.
80. Noguera A, Ros JB, Pavia C, Alcover E, Valls C, Villaronga M et al. Bisphosphonates, a new treatment for glucocorticoids-induced osteoporosis in children. J Pediatr Endocrinol Metab 2003; 16(4):529-36.
81. Thornton J, Ashcroft DM, Mughal MZ, Elliott RA, O'Neill TW, Symmons D. Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis. Arch Dis Child 2006; 91(9):753-61.
82. Batch JA, Couper JJ, Rodda C, Cowell CT, Zacharin M. Use of bisphosphonte therapy for osteoporosis in childhood and adolescence. J Paediatr Child Health 2003; 39(2):88-92.